Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jan 04, 2024 10:49am
90 Views
Post# 35810434

RE:RE:RE:RE:black out is over, but where's the beef?

RE:RE:RE:RE:black out is over, but where's the beef?
Hey Azzak thanks for bringing me in on this conversation as I was not going to post on this board but since you brought it up. Think about it in regards to the Bracelet trial, all results (except the ci arm) showed similar results to the original mbc 213 and the AN bridgiing trial also showed similar positive results so it they had run the trial way back when the trial would have been done good or bad and we would know. And they would have spent the same amount of money by now. It is only my opinion but even AN wanted to run the phase 3 but didn't as I understand they had to have the approval of onc to run the trial and now pela is not even the list for AN.
Well at least according to some the company has saved us a lot of money, time and patients by spending millions of dollars over a few years and then even messing up the Bracelet trial by removing patients with fever issues which was a huge mistake.


<< Previous
Bullboard Posts
Next >>